Wnt2 expression and signaling is increased by different classes of antidepressant treatments

Hideki Okamoto, Bhavya Voleti, Mounira Banasr, Maysa Sarhan, Vanja Duric, Matthew J. Girgenti, Ralph J. Dileone, Samuel S. Newton, Ronald S. Duman

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Background: Despite recent interest in glycogen synthase kinase-3β (GSK-3β) as a target for the treatment of mood disorders, there has been very little work related to these illnesses on the upstream signaling molecules that regulate this kinase as well as downstream targets. Methods: With a focused microarray approach we examined the influence of different classes of antidepressants on Wnt signaling that controls GSK-3β activity as well as the transcription factors that contribute to the actions of GSK-3β. Results: The results demonstrate that Wnt2 is a common target of different classes of antidepressants and also show differential regulation of Wnt-GSK-3β signaling genes. Increased expression and function of Wnt2 was confirmed by secondary measures. Moreover, with a viral vector approach we demonstrate that increased expression of Wnt2 in the hippocampus is sufficient to produce antidepressant-like behavioral actions in well-established models of depression and treatment response. Conclusions: These findings demonstrate that Wnt2 expression and signaling is a common target of antidepressants and that increased Wnt2 is sufficient to produce antidepressant effects.

Original languageEnglish (US)
Pages (from-to)521-527
Number of pages7
JournalBiological Psychiatry
Volume68
Issue number6
DOIs
StatePublished - Sep 15 2010

Fingerprint

Glycogen Synthase Kinase 3
Antidepressive Agents
Mood Disorders
Hippocampus
Transcription Factors
Phosphotransferases
Depression
Genes

Keywords

  • Antidepressants
  • Wnt signaling
  • depression

ASJC Scopus subject areas

  • Biological Psychiatry

Cite this

Okamoto, H., Voleti, B., Banasr, M., Sarhan, M., Duric, V., Girgenti, M. J., ... Duman, R. S. (2010). Wnt2 expression and signaling is increased by different classes of antidepressant treatments. Biological Psychiatry, 68(6), 521-527. https://doi.org/10.1016/j.biopsych.2010.04.023

Wnt2 expression and signaling is increased by different classes of antidepressant treatments. / Okamoto, Hideki; Voleti, Bhavya; Banasr, Mounira; Sarhan, Maysa; Duric, Vanja; Girgenti, Matthew J.; Dileone, Ralph J.; Newton, Samuel S.; Duman, Ronald S.

In: Biological Psychiatry, Vol. 68, No. 6, 15.09.2010, p. 521-527.

Research output: Contribution to journalArticle

Okamoto, H, Voleti, B, Banasr, M, Sarhan, M, Duric, V, Girgenti, MJ, Dileone, RJ, Newton, SS & Duman, RS 2010, 'Wnt2 expression and signaling is increased by different classes of antidepressant treatments', Biological Psychiatry, vol. 68, no. 6, pp. 521-527. https://doi.org/10.1016/j.biopsych.2010.04.023
Okamoto, Hideki ; Voleti, Bhavya ; Banasr, Mounira ; Sarhan, Maysa ; Duric, Vanja ; Girgenti, Matthew J. ; Dileone, Ralph J. ; Newton, Samuel S. ; Duman, Ronald S. / Wnt2 expression and signaling is increased by different classes of antidepressant treatments. In: Biological Psychiatry. 2010 ; Vol. 68, No. 6. pp. 521-527.
@article{d1be8f02e03a46af9bc54f7c41b01d62,
title = "Wnt2 expression and signaling is increased by different classes of antidepressant treatments",
abstract = "Background: Despite recent interest in glycogen synthase kinase-3β (GSK-3β) as a target for the treatment of mood disorders, there has been very little work related to these illnesses on the upstream signaling molecules that regulate this kinase as well as downstream targets. Methods: With a focused microarray approach we examined the influence of different classes of antidepressants on Wnt signaling that controls GSK-3β activity as well as the transcription factors that contribute to the actions of GSK-3β. Results: The results demonstrate that Wnt2 is a common target of different classes of antidepressants and also show differential regulation of Wnt-GSK-3β signaling genes. Increased expression and function of Wnt2 was confirmed by secondary measures. Moreover, with a viral vector approach we demonstrate that increased expression of Wnt2 in the hippocampus is sufficient to produce antidepressant-like behavioral actions in well-established models of depression and treatment response. Conclusions: These findings demonstrate that Wnt2 expression and signaling is a common target of antidepressants and that increased Wnt2 is sufficient to produce antidepressant effects.",
keywords = "Antidepressants, Wnt signaling, depression",
author = "Hideki Okamoto and Bhavya Voleti and Mounira Banasr and Maysa Sarhan and Vanja Duric and Girgenti, {Matthew J.} and Dileone, {Ralph J.} and Newton, {Samuel S.} and Duman, {Ronald S.}",
year = "2010",
month = "9",
day = "15",
doi = "10.1016/j.biopsych.2010.04.023",
language = "English (US)",
volume = "68",
pages = "521--527",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier USA",
number = "6",

}

TY - JOUR

T1 - Wnt2 expression and signaling is increased by different classes of antidepressant treatments

AU - Okamoto, Hideki

AU - Voleti, Bhavya

AU - Banasr, Mounira

AU - Sarhan, Maysa

AU - Duric, Vanja

AU - Girgenti, Matthew J.

AU - Dileone, Ralph J.

AU - Newton, Samuel S.

AU - Duman, Ronald S.

PY - 2010/9/15

Y1 - 2010/9/15

N2 - Background: Despite recent interest in glycogen synthase kinase-3β (GSK-3β) as a target for the treatment of mood disorders, there has been very little work related to these illnesses on the upstream signaling molecules that regulate this kinase as well as downstream targets. Methods: With a focused microarray approach we examined the influence of different classes of antidepressants on Wnt signaling that controls GSK-3β activity as well as the transcription factors that contribute to the actions of GSK-3β. Results: The results demonstrate that Wnt2 is a common target of different classes of antidepressants and also show differential regulation of Wnt-GSK-3β signaling genes. Increased expression and function of Wnt2 was confirmed by secondary measures. Moreover, with a viral vector approach we demonstrate that increased expression of Wnt2 in the hippocampus is sufficient to produce antidepressant-like behavioral actions in well-established models of depression and treatment response. Conclusions: These findings demonstrate that Wnt2 expression and signaling is a common target of antidepressants and that increased Wnt2 is sufficient to produce antidepressant effects.

AB - Background: Despite recent interest in glycogen synthase kinase-3β (GSK-3β) as a target for the treatment of mood disorders, there has been very little work related to these illnesses on the upstream signaling molecules that regulate this kinase as well as downstream targets. Methods: With a focused microarray approach we examined the influence of different classes of antidepressants on Wnt signaling that controls GSK-3β activity as well as the transcription factors that contribute to the actions of GSK-3β. Results: The results demonstrate that Wnt2 is a common target of different classes of antidepressants and also show differential regulation of Wnt-GSK-3β signaling genes. Increased expression and function of Wnt2 was confirmed by secondary measures. Moreover, with a viral vector approach we demonstrate that increased expression of Wnt2 in the hippocampus is sufficient to produce antidepressant-like behavioral actions in well-established models of depression and treatment response. Conclusions: These findings demonstrate that Wnt2 expression and signaling is a common target of antidepressants and that increased Wnt2 is sufficient to produce antidepressant effects.

KW - Antidepressants

KW - Wnt signaling

KW - depression

UR - http://www.scopus.com/inward/record.url?scp=77956178815&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956178815&partnerID=8YFLogxK

U2 - 10.1016/j.biopsych.2010.04.023

DO - 10.1016/j.biopsych.2010.04.023

M3 - Article

C2 - 20570247

AN - SCOPUS:77956178815

VL - 68

SP - 521

EP - 527

JO - Biological Psychiatry

JF - Biological Psychiatry

SN - 0006-3223

IS - 6

ER -